Reuters logo
BRIEF-Protalix Biotherapeutics initiates PRX-102 global phase III clinical trial
2016年6月6日 / 上午11点12分 / 1 年前

BRIEF-Protalix Biotherapeutics initiates PRX-102 global phase III clinical trial

June 6 (Reuters) - Protalix Biotherapeutics Inc :

* Initiates PRX-102 global phase III clinical trial of fabry disease to support United States and European filings Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below